Alectinib | List of Frontiers open access articles

Case Report

Published on 17 Aug 2023

Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy

in Pharmacology of Anti-Cancer Drugs

Peijun Cao
Qingchun Zhao
Yongwen Li
Ruifeng Shi
Guangsheng Zhu
Zihe Zhang
Hongbing Zhang
Minghui Liu
Sen Wei
Hongyu Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1140894

2,951 views
2 citations

Case Report

Published on 21 May 2025

Perforation of the descending colon induced by alectinib in a patient with non-small cell lung cancer: a Case Report

in Pharmacology of Anti-Cancer Drugs

Yun Li
Ping Yu
Ran Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1545614

1,648 views
1 citation

Case Report

Published on 01 Nov 2022

Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer

in Pharmacology of Anti-Cancer Drugs

Xianmeng Chen
Daqing Xia
Xuqin Jiang
Lejie Cao
Jay H. Ryu
Xiaowen Hu

Frontiers in Pharmacology

doi 10.3389/fphar.2022.944685

3,970 views
4 citations

Original Research

Published on 21 Oct 2024

A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring ALK rearrangement

in Thoracic Oncology

Zeng-Hao Chang
Teng-Fei Zhu
Wei Ou
Hao Jiang
Si-Yu Wang

Frontiers in Oncology

doi 10.3389/fonc.2024.1422035

3,935 views
5 citations

Case Report

Published on 26 Sep 2024

Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports

in Thoracic Oncology

Paul Wheatley-Price
Boaz Wong
Hely Shah
Harman Sekhon
Sara Moore

Frontiers in Oncology

doi 10.3389/fonc.2024.1398414

1,971 views
1 citation

Systematic Review

Published on 20 Jun 2023

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports

in Thoracic Oncology

Liang Shi
Shuhong Gao
Li Tong
Qiyi Meng
Shijie Zhou
Daping Yu
Yujie Dong
Zhe Liu

Frontiers in Oncology

doi 10.3389/fonc.2023.1120511

4,181 views
7 citations

Study Protocol

Published on 09 Mar 2023

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)

in Thoracic Oncology

Marinda Meertens
M. Benthe Muntinghe-Wagenaar
Barend J. Sikkema
Marta Lopez-Yurda
Valesca P. Retèl
Marthe S. Paats
Rob Ter Heine
Ed Schuuring
Wim Timens
Daan J. Touw

Frontiers in Oncology

doi 10.3389/fonc.2023.1136221

10,968 views
11 citations

Case Report

Published on 19 Aug 2021

STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report

in Molecular and Cellular Oncology

Chunlai Feng
Rong Zhou
Feng Liu
Tingting Wang
Sisi Liu
Yang Shao

Frontiers in Oncology

doi 10.3389/fonc.2021.700341

3,350 views
2 citations

Original Research

Published on 02 Jun 2021

Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis

in Thoracic Oncology

Hao Tang
Longyu Jin
Zhang Zhang
Zhibin Jiang
Zeeshan Malik

Frontiers in Oncology

doi 10.3389/fonc.2021.646526

8,705 views
10 citations

Original Research

Published on 29 Jul 2024

ROS1 kinase inhibition reimagined: identifying repurposed drug via virtual screening and molecular dynamics simulations for cancer therapeutics

in Medicinal and Pharmaceutical Chemistry

Mohammed Alrouji
Sabina Yasmin
Fahad A Alhumaydhi
Sharaf E. Sharaf
Moyad Shahwan
Anas Shamsi

Frontiers in Chemistry

doi 10.3389/fchem.2024.1392650

2,679 views

Mini Review

Published on 30 Nov 2016

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC

in Pathology

Phu N. Tran
Samuel J. Klempner

Frontiers in Medicine

doi 10.3389/fmed.2016.00065

8,639 views
10 citations

Original Research

Published on 05 Feb 2026

The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer

in Health Economics

Xuanxuan Yan
Sijuan Zhou
Jiahao Hu
Yan Xia
Haotian He
Nick Jovanoski
Melina Arnold
Jian Hu
Pingping Song
Benyuan Jiang

Frontiers in Public Health

doi 10.3389/fpubh.2025.1571980

762 views

Case Report

Published on 06 Jul 2022

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer

in Pharmacology of Anti-Cancer Drugs

Yan Hu
Siying Ren
Ruoyao Wang
Wei Han
Peng Xiao
Li Wang
Fenglei Yu
Wenliang Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2022.816683

4,496 views
11 citations

Case Report

Published on 12 Jan 2023

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review

in Cancer Molecular Targets and Therapeutics

Yuri Isaka
Akinori Sasaki
Akira Saito
Yasuaki Motomura
Yayoi Ando
Yoshiaki Nakamura

Frontiers in Oncology

doi 10.3389/fonc.2022.1064944

2,482 views
1 citation

Original Research

Published on 24 Sep 2025

Computational drug repurposing reveals Alectinib as a potential lead targeting Cathepsin S for therapeutic developments against cancer and chronic pain

in Drug Discovery in Bioinformatics

Mohammed Alrouji
Mohammed S. Alshammari
Sharif Alhajlah
Syed Tasqeeruddin
Khuzin Dinislam
Anas Shamsi
Saleha Anwar

Frontiers in Bioinformatics

doi 10.3389/fbinf.2025.1666573

2,604 views

Case Report

Published on 09 Nov 2022

Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report

in Cancer Molecular Targets and Therapeutics

Lucheng Zhu
Shenglin Ma
Bing Xia

Frontiers in Oncology

doi 10.3389/fonc.2022.1009076

3,206 views
7 citations

Articles

Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy

Perforation of the descending colon induced by alectinib in a patient with non-small cell lung cancer: a Case Report

Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer

A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring ALK rearrangement

Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)

STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report

Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis

ROS1 kinase inhibition reimagined: identifying repurposed drug via virtual screening and molecular dynamics simulations for cancer therapeutics

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC

The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review

Computational drug repurposing reveals Alectinib as a potential lead targeting Cathepsin S for therapeutic developments against cancer and chronic pain

Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report